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T
he investigation by The BMJ and 
Cambridge and Bath universities into the 
availability of breakthrough hepatitis C  
drugs raises important questions for 
NHS England about access to lifesaving 
drugs.1 But why are medicines so expensive in the irst 
place? The pricing strategy of Gilead for sofosbuvir 
(Sovaldi) and ledipasvir-sofosbuvir (Harvoni) raises  
questions that go well beyond the UK.
The BMJ’s investigation is just an example of a more 
general problem. What is the right price to pay for a 
particular drug, and how should this be determined?
Pharmaceutical innovation should be structured 
to focus on unmet health needs globally and 
delivers therapeutic advances that are afordable 
and accessible to all,2 not just proitable for 
manufacturers. This requires an approach that directs 
efort towards therapeutic innovations over “me 
too” drugs, and a transparent inancing and pricing 
structure, focused on access, and relecting the 
collective investment and risk taking involved.
Drug companies have oten ignored the collective 
element of innovation and argued that their 
research and development investment justiies the 
extraordinarily high prices for some medicines, 
despite the lack of transparency. The Drugs for 
Neglected Diseases initiative has documented 
much lower drug development costs,3 4 and several 
authors have shown the extent to which taxpayer 
funded investments subsidises those costs.5 In the 
US alone, tax payers fund $32bn a year of research 
and development expenditure through the National 
Institutes of Health (NIH).6
Value judgment 
Sofosbuvir and ledipasvir, the drugs on which 
The BMJ investigation is based, relied on early 
stage funding from the NIH and the Veterans 
Administration.7 Sales of the two drugs were around 
$12bn in 2014,8 far in excess of the $880.3m which 
Gilead reported for sofosbuvir related trials from 
2012 to 2014,7 showing a complete disconnection 
between price and development costs.
As high prices are hard to justify based on research 
and development costs, drug companies have 
instead argued that their prices are proportionate 
to the intrinsic value of the drugs—that is, the costs 
to society if a disease was not treated, or if treated 
with the second best therapy available. “Price is the 
wrong discussion,” declared Gilead’s executive vice 
president, Gregg Alton, responding to criticism over 
the price of sofosbuvir, “value should be the subject.”9
But there is no consistent link between a drug’s 
price and the associated medical beneit.10 A study 
published in 2015 in the Journal of Economic 
Perspectives examining a sample of 58 cancer 
drugs approved in the US between 1995 and 2013, 
shows that the increasing trend in the price of 
these medicines is not explained by the survival 
beneits they provide. Over two thirds of new 
medicines reaching the market do not represent 
any therapeutic advance for patients, with many 
patents based on a reshuling of old combinations 
or additional uses for existing ones.11
A better way
An efective pricing system should ensure 
accessibility and relect the public contribution 
so taxpayers don’t pay twice, through publicly 
subsidised research and high priced medicines. 
In such a system, drug prices do not need to be so 
much higher than manufacturing costs. We could, 
for example, limit patents on new medicines (the 
current source of company proits) and instead 
establish a competitive prize system that rewards 
well targeted pharmaceutical innovation. This 
would allow widespread access to drugs at 
competitive prices through generics, while pushing 
drug companies to focus their energy on delivering 
innovations that fulil real medical need. In any 
case, patents should not be so upstream to afect 
scientiic research, and should remain relatively 
narrow so as not to close of future discoveries.12 
They should foster innovation, not stile it.
Importantly, drug pricing must be transparent, 
so that governments can negotiate for better value 
and ensure that the prices of new drugs relect the 
burden of inancial risk borne by the taxpayer. 
Public funders could retain the lion’s share of 
intellectual property rights (patents) produced 
by public research so that spillovers through 
licensing can be better managed to foster difusion. 
In the US, the 1980 Bayh-Dole Act that allowed 
publicly funded research to be patented includes 
a clause enabling the government to cap the prices 
of drugs that are largely publicly funded. The US 
government has never exercised this right.13
The international debate about unsustainable 
drug prices, including those for hepatitis C drugs, 
ofers an opportunity to rethink the therapeutic 
innovation ecosystem—the direction and the 
accessibility of the drugs that result. Realising that 
government has power to actively shape and create 
markets, and not just remain on the sidelines 
ixing broken ones, is the irst important step to 
reaching a better deal.14 15
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